Mekinist: latest news - GoINPHARMA
Saturday, 15 December 2018 - 6:19


BMS, Novartis strike partnership to assess Opdivo-Mekinist combination

Novartis and Bristol-Myers Squibb announced a collaboration to assess the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) as a potential treatment option for metastatic colorectal cancer in a certain patients…

Novartis’ Tafinlar–Mekinist combo therapy approved for lung cancer

European authority EMA approved Tafinlar–Mekinist combined therapy for the treatment of BRAF V600 mutation-driven lung cancer. The mutation affects 1 to 3% (36,000) of lung cancer cases worldwide. The two therapies generated $672m in revenue last year. The approval follows…